UNCY Logo.jpg
Unicycive Announces Third Quarter 2023 Financial Results and Provides Business Update
14 nov. 2023 16h15 HE | Unicycive Therapeutics, Inc.
Reached Alignment with the FDA on the Data Package Requirements to File NDA for oxylanthanum carbonate (OLC) OLC Pivotal Clinical Trial Expected to Initiate Before Year End LOS ALTOS, Calif., Nov. ...
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Announces Article in Peer-Reviewed Journal, Ecotoxicology and Environmental Safety, Linking Air Pollution with Development and Progression of Chronic Kidney Disease That Can Be Attenuated by Inhibiting Inflammasome NLRP3 Activation
06 nov. 2023 07h05 HE | ZyVersa Therapeutics
Air pollution linked with development and progression of chronic kidney disease that can be attenuated by inhibiting inflammasome NLRP3 activation.
UNCY Logo.jpg
Unicycive Therapeutics Reaches Alignment with the FDA on Path to File New Drug Application for Oxylanthanum Carbonate (OLC)
23 oct. 2023 07h03 HE | Unicycive Therapeutics, Inc.
- Pivotal clinical trial expected to initiate before year end - LOS ALTOS, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology...
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Announces a Publication in the Peer-Reviewed Journal, Aging, Linking Inflammasome NLRP3 Activation with Age-Related Structural Changes in the Kidney and Reduced Kidney Function
18 oct. 2023 07h05 HE | ZyVersa Therapeutics
Inflammasome NLRP3 activation is associated with an age-related decline in kidney health, which is compounded in the presence of kidney disease.
Global Kidney Diseases Market
Rising Incidence of Kidney Disorders Boosts Kidney Disease Market: Over 37 Million Americans Affected, Highlighting Growing Demand for Treatment Solutions
12 oct. 2023 07h13 HE | Research and Markets
Dublin, Oct. 12, 2023 (GLOBE NEWSWIRE) -- The "Kidney Disease Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global kidney diseases market is...
Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company Join American Kidney Fund’s 2023 Corporate Membership Program at ‘Champion’ Level
06 oct. 2023 11h28 HE | American Kidney Fund
ROCKVILLE, Md., Oct. 06, 2023 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today announced that Boehringer Ingelheim and Eli Lilly and Company have joined the 2023 class in AKF’s Corporate...
American Kidney Fund
American Kidney Fund Launches Educational Awareness Campaigns for Two Rare Kidney Diseases
26 sept. 2023 09h18 HE | American Kidney Fund
ROCKVILLE, Md., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Today, the American Kidney Fund (AKF) launched educational awareness campaigns for two rare kidney diseases: complement 3 glomerulopathy (C3G) and...
American Kidney Fund
American Kidney Fund, Home Dialyzors United Partner to Host Second Annual Dialysis at Home Summit
12 sept. 2023 10h24 HE | American Kidney Fund
ROCKVILLE, Md., Sept. 12, 2023 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) has partnered with Home Dialyzors United, a nonprofit advocating on behalf of the home dialyzor community, to host...
Travere Therapeutics
Travere Therapeutics Joins American Kidney Fund’s 2023 Corporate Membership Program at ‘Champion’ Level
08 sept. 2023 09h51 HE | American Kidney Fund
ROCKVILLE, Md., Sept. 08, 2023 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today announced that Travere Therapeutics has joined the 2023 class in AKF’s Corporate Membership Program as a...
Amgen Joins American
Amgen Joins American Kidney Fund’s 2023 Corporate Membership Program at ‘Champion’ Level
06 sept. 2023 09h10 HE | American Kidney Fund
ROCKVILLE, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today expressed its appreciation for Amgen’s participation in the 2023 class of its Corporate Membership Program as...